Multiple Myeloma Insights

D-Vrd Supports Transplant-Ineligible Multiple Myeloma Patients

April 23, 2025

Latest Research

A recent study screened 47 human multiple myeloma cell lines against small-molecule compounds to identify potential new treatments. This effort aims to help researchers discover drugs that could target the disease more effectively, particularly for patients who don’t respond well to existing therapies.

The dataset provides a detailed map of how these myeloma cells react to various chemical compounds, which could accelerate the development of personalized treatments. While the study doesn’t report specific drug candidates yet, it creates a valuable resource for future research into tailored approaches for this blood cancer, as noted by (Hughitt, 2025).

Clinical Trials

This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

National Cancer Institute "Cancer Moonshot Biobank"

View the full list of clinical trials →

Community News

Multiple Myeloma Research FoundationApr 16, 2025

Anne Quinn Young, MPH, Chief Mission Officer at the Multiple Myeloma Research Foundation, gets answers to frequently asked questions on how to effectively communicate with your care team and optimize your care from MMRF founder Kathy Giusti and Patient Navigator Erin Mensching.

Ms. Young gets insights on effective communication from Ms. Giusti and Ms. Mensching on such topics as...

· How to maximize every appointment

· Getting a second opinion

· Key questions to ask

· How to get the most out of treatment while clearly communicating your personal goals and priorities

This session is supported by Adaptive, Bristol Myers Squibb, CURE, Genentech, Kite/Arcellx, Pfizer, and Sanofi.

If you have questions, call our MMRF Patient Navigation Center at 1-888-841-6673.

International Myeloma FoundationApr 18, 2025

What is CAR T-cell therapy, and how does it work to treat multiple myeloma? In this quick, easy-to-understand video, IMF Chief Medical Officer Dr. Joseph Mikhael breaks down the CAR T-cell therapy process in under one minute.